All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-YC0572 | Human anti-Insulin B T cell receptor (20D11), pCDTCR1 | 20D11 | Human | SHLVEALYLVCGEEG | HLA-DQA1*03:01/DQB1*03:02 | Lentiviral vector | ||
TCR-YC0573 | Human anti-Insulin B T cell receptor (6.H9), pCDTCR1 | Human | 6.H9 | Human | SHLVEALYLVCGEEG | HLA-DQB1*03:02 | Lentiviral vector | |
TCR-YC0574 | Mouse anti-Insulin B T cell receptor (8-1.1), pCDTCR1 | 8-1.1 | Mouse | HLVERLYLVCGGE | H2-IAg7 | Lentiviral vector | ||
TCR-YC0575 | Mouse anti-Insulin B T cell receptor (8F10), pCDTCR1 | 8F10 | Mouse | HLVERLYLVCGGE | H2-IAg7 | Lentiviral vector | ||
TCR-YC0576 | Mouse anti-Insulin B T cell receptor (I.29), pCDTCR1 | I.29 | Mouse | HLVERLYLVCGEE | H2-IAg7 | Lentiviral vector | ||
TCR-YC0577 | Mouse anti-Insulin B T cell receptor ((PCR10.1)-1), pCDTCR1 | PCR10.1 | Mouse | HLVERLYLVCGEE | H2-IAg7 | Lentiviral vector | ||
TCR-YC0578 | Mouse anti-Insulin B T cell receptor ((PCR10.1)-2), pCDTCR1 | PCR10.1 | Mouse | HLVERLYLVCGGE | H2-IAg7 | Lentiviral vector | ||
TCR-YC0579 | Human anti-Insulin B T cell receptor (T1D-10), pCDTCR1 | T1D-10 | Human | HLVEELYLVAGEEGC (α72) | HLA-DQ8 | Lentiviral vector | ||
TCR-YC0580 | Human anti-Insulin B T cell receptor (T1D-3), pCDTCR1 | T1D-3 | Human | HLVEELYLVAGEEGC (α72) | HLA-DQ8 | Lentiviral vector | ||
TCR-YC0581 | Human anti-Insulin B T cell receptor (T1D-4), pCDTCR1 | T1D-4 | Human | HLVEELYLVAGEEGC (α72) | HLA-DQ8 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION